If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.
Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
In 2020, Darzalex Faspro (the Sub-Q version) changed the game. The infusion time went from three hours (or an hour and a half ...
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 ...
Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...
Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...
Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback